[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551535":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Juventas Cell Therapy Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":12},"OTHER","Inaticabtagene autoleucel Injection",[13],"CNCT19",[15],{"name":16,"affiliation":17,"role":18},"Jianxiang Wang, Dr.","Institute of Hematology & Blood Diseases Hospital, Tianjin, China","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Yinling Wu","CONTACT","+86 13161292425","wuyinling@juventas.cn",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":7,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],117.17667,39.14222,{"lat":37,"lon":36},[40],{"name":16,"role":22,"phone":7,"phoneExt":7,"email":7},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100551535","long-term-observational-study-of-patients-treated-with-inaticabtagene-autoleucel-injection-100551535",false,"NCT06461351","Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection","A Long Term Follow-up Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection","Inclusion Criteria:\n\n1. Agree to sign an informed consent form for long-term follow-up studies.\n2. Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients.\n\nExclusion Criteria:\n\n\\- None.","ALL","18 Years",{"count":53,"type":54},1000,"ESTIMATED","OBSERVATIONAL","This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.",[58],"B-cell Tumors","2025-08-06",{"date":61,"type":62},"2025-08-07","ACTUAL",{"date":64,"type":62},"2024-03-30",{"date":66,"type":54},"2040-03-30",{"name":5,"class":6},1]